Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
5
Drug Approvals
Mycophenolate Sodium Enteric-coated Tablets
- Product Name
- 麦考酚钠肠溶片
- Approval Number
- 国药准字HJ20240002
- Approval Date
- Jan 9, 2024
Mycophenolate Sodium Enteric-coated Tablets
- Product Name
- 麦考酚钠肠溶片
- Approval Number
- 国药准字HJ20240003
- Approval Date
- Jan 9, 2024
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
News
Sandoz Plans Generic Semaglutide Launch in Canada with Up to 70% Price Reduction
Swiss generic manufacturer Sandoz plans to launch unbranded semaglutide weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents expire next year.
Stelara Biosimilars Capture Market Share as J&J's Blockbuster Drug Faces 33.7% Sales Decline
Johnson & Johnson's Stelara experienced a dramatic 33.7% year-over-year sales decline to $1.08 billion in Q1 2025, driven by aggressive biosimilar competition following patent expiration in September 2023.
Anthem Biosciences Positions as China Alternative in $3.4 Billion IPO Amid Global Supply Chain Shift
Anthem Biosciences is launching a ₹3,395 crore IPO next week, positioning itself as a key alternative to Chinese CRDMOs as global pharma companies diversify supply chains amid geopolitical uncertainties.
Biocon Races to Launch First Generic Semaglutide in Canada as Wegovy Patents Expire
Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026.
Regeneron Navigates EYLEA Decline with Pipeline Diversification and Regulatory Wins
Regeneron reported challenging Q1 2025 results with total revenues declining 4% to $3.029 billion, primarily driven by EYLEA franchise headwinds from biosimilar competition and pricing pressures.
Regeneron Expands Patent Protection for Aflibercept with New Formulation Patent Against Amgen
Regeneron filed a new patent infringement complaint against Amgen on June 17, 2025, asserting U.S. Patent No. 12,331,099 covering a stable liquid ophthalmic formulation without buffer requirements.
Biocon Receives CDSCO Approval for Liraglutide Diabetes Drug in India
Biocon has received regulatory approval from India's Central Drugs Standard Control Organisation (CDSCO) for its diabetes drug liraglutide, marking a significant milestone for the company's pharmaceutical portfolio.
Biocon Receives Indian Regulatory Approval for Generic Liraglutide, Expanding GLP-1 Diabetes Treatment Access
Biocon Limited has received approval from India's CDSCO for its generic version of Victoza (liraglutide), marking the company's first vertically integrated GLP-1 diabetes therapy clearance in the country.
Biocon Plans ₹4,500 Crore QIP to Reduce Debt and Increase Biologics Stake
Biocon chairperson Kiran Mazumdar-Shaw announced plans for a ₹4,500 crore qualified institutional placement to convert structured venture debt into equity, aiming to strengthen the company's balance sheet.
Biocon Announces $150 Million Capital Expenditure Plan Amid Strong Q4 Performance
• Biocon plans to invest $150 million in capital expenditure over the next two years, with $100 million allocated to biologics expansion in Malaysia and $50 million to generics. • The biopharmaceutical company reported a 153% surge in Q4 net profit to Rs 344 crore, driven by strong growth in generics and steady progress in biosimilars. • Biocon is expanding its product portfolio with recent launches of lenalidomide and dasatinib in the US, liraglutide in the UK, and plans to launch bevacizumab and insulin aspart in the US market.